STOCKSCREENR
Log In

VRAX

NASDAQ

Virax Biolabs Group Limited

$0.20+0.02(+8.74%)Mkt Cap: $880.11K

Key Stats

Market Cap

$880.11K

P/E Ratio

-0.17

EPS

$-1.22

Dividend Yield

0.00%

52-Week Range

$0.18 — $1.35

Volume

153.87K

Avg Volume

296.46K

Beta

1.71

Valuation

P/E (TTM)

-0.17

Forward P/E

—

PEG Ratio

-0.01

P/S (TTM)

277.73

P/B (TTM)

0.17

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-1.03%

ROA (TTM)

-0.99%

ROIC

—

Gross Margin

-87.75%

Operating Margin

-1965.67%

Net Margin

—

Debt/Equity

0.10

Current Ratio

11.35

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

-0.55%

EPS Growth (5Y)

-0.62%

Sales Growth (3Y)

+5.44%

Sales Growth (5Y)

+3.11%

EPS Est (This Year)

$-0.40

EPS Est (Next Year)

$-0.24

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$0.70

Analyst Consensus

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

—

Outstanding Shares

4.34M

Float

3.90M

Free Float %

89.91%

About

Sector

Healthcare

Industry

Biotechnology

Country

GB

Exchange

NASDAQ

IPO Date

2022-07-21

Employees

17

CEO

James Foster

Index Membership

—

Website

https://viraxbiolabs.com

Virax Biolabs Group Limited (VRAX) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $880.11K, a P/E ratio of -0.17, VRAX is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare VRAX against other stocks using dozens of fundamental and technical filters.

Similar Stocks

IBO.V

Universal Ibogaine Inc.

$0.01

-50.00%

$1.56M

ASBP

Aspire Biopharma Holdings, Inc.

$0.88

-10.21%

$3.03M

BRTX

BioRestorative Therapies, Inc.

$0.25

-12.40%

$2.24M

CARM

Carisma Therapeutics, Inc.

$0.04

+2.70%

$1.59M

INM

InMed Pharmaceuticals Inc.

$0.89

+3.30%

$1.61M

DRMA

Dermata Therapeutics, Inc.

$1.22

+1.67%

$831.50K

Frequently Asked Questions

What is Virax Biolabs Group Limited's P/E ratio?

Virax Biolabs Group Limited (VRAX) has a trailing twelve-month (TTM) P/E ratio of -0.17. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Virax Biolabs Group Limited pay a dividend?

No, Virax Biolabs Group Limited (VRAX) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Virax Biolabs Group Limited's market cap?

Virax Biolabs Group Limited (VRAX) has a market capitalization of $880,114, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.